Journey Medical Corporation

DERM

US48115J1097

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
5.66 ^USD	-0.35%		+8.64%	-1.74%

Jul. 11	Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors	CI
May. 13	Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024

Journey Medical Corporation Announces Postponement of Financial Results for the First Quarter of 2023

May 11, 2023 at 04:47 pm EDT

Journey Medical Corporation announced that it has postponed the release of its first fiscal quarter financial results, previously scheduled for May 11, 2023, to provide additional time to complete the finalization of its financial statements.

Latest news about Journey Medical Corporation

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors	Jul. 11	CI
Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024	May. 13
Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q1 Revenue $13M, vs. Street Est of $14.1M	May. 13	MT
Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer	May. 01	CI
Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024	Mar. 21
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	Mar. 18	CI
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting	Mar. 11	CI
Alliance Global Partners Starts Coverage on Journey Medical With Buy Rating, $8.50 Price Target	Feb. 16	MT
Journey Medical Submits New Drug Application to FDA for Rosacea Treatment; Shares Rise	Jan. 05	MT
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	Jan. 05	CI
Journey Medical Signs Credit Facility of up to $20 Million	Jan. 02	MT
Journey Medical Corporation Secures Credit Facility with SWK Holdings for Up to $20 Million	Jan. 02	CI
Journey Medical Corporation Announces Resignation of Jeffrey Paley as Member of the Board of Directors	Dec. 08	CI
B. Riley Lifts Journey Medical's PT to $8 From $6 After US FDA Gives Green Light for DFD-29's Year-End 2023 Filing, Keeps Buy Rating	Dec. 07	MT
Journey Medical Corporation Announces Successful Completion of Pre-Nda Meeting with the Fda for Dfd-29 to Treat Rosacea	Dec. 06	CI
Journey Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Transcript : Journey Medical Corporation, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Reports Q3 Revenue $34.5M	Nov. 07	MT
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q3 EPS $0.99	Nov. 07	MT
Journey Medical Says Study Shows Bioavailability of Minocycline Lower After One Dose of DFD-29 Compared With Solodyn	23-10-20	MT
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29	23-10-20	CI
Insider Buy: Journey Medical	23-09-08	MT
Journey Medical Grants Exclusive License to Maruho for Manufacturing, Commercialization of Qbrexza in Asia	23-09-06	MT

Chart Journey Medical Corporation

Duration

Period

More charts

Company Profile

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Journey Medical Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.66 USD

Average target price

9.167 USD

Spread / Average Target

+61.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOURNEY MEDICAL CORPORATION	-1.74%	113M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals